Ask AI

Experts in the Hot Seat: Forging Ahead in Infant RSV Prevention

Respiratory syncytial virus (RSV) in infants remains a leading cause of outpatient visits, hospitalizations, and even mortality, despite a growing prevention armamentarium, including maternal vaccines and monoclonal antibodies (mAbs) for infant immunization. Use this program to learn how to tailor infant RSV prevention strategies to the needs of individual infants and caregivers, including how to navigate growing uncertainty about vaccines.

Share

Program Content

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

 

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

 

Merck & Co., Inc., Rahway, NJ, USA